Bruker Corporation
BRKR
Rankning i aktier
#2309
Bruker Corporation stands as a prominent global developer, manufacturer, and... Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its operations are structured across three distinct segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. The company's extensive portfolio for life sciences encompasses a variety of advanced tools, including single and multi-modality systems, sophisticated mass spectrometry platforms, and critical diagnostic solutions. These diagnostics feature the acclaimed MALDI Biotyper for swift pathogen identification, various molecular diagnostic kits (such as genotype and fluorotype offerings), DNA test strips, and fluorescence-based polymerase chain reaction (PCR) technology, notably including SARS-CoV-2 testing solutions for COVID-19 diagnosis and Fluorotyper-SARS-CoV-2 plus kits. Beyond life science, Bruker delivers a wide array of specialized instruments for research, analysis, and process control. This includes portable analytical and bioanalytical detection systems, a full range of X-ray instruments (from analytical tools for electron microscopes to handheld, portable, and mobile X-ray fluorescence spectrometry devices), and sophisticated atomic force microscopy (AFM) instrumentation for non-contact nanometer resolution topography. Furthermore, it supplies automated X-ray metrology, automated AFM defect-detection, and equipment for photomask repair and cleaning. The company also excels in advanced optical fluorescence microscopy and provides critical products and services supporting multi-omics research for drug and biomarker discovery. Within its energy sector, Bruker is a key provider of superconducting materials, particularly metallic low-temperature superconductors, and develops complex tools and devices utilizing these materials, alongside other high-technology tools like synchrotron and beamline instrumentation. Reflecting its commitment to innovation, Bruker Corporation collaborates with Newomics Inc. on an LC-MS platform specifically tailored for drug discovery applications. Established in 1991, the corporation maintains its headquarters in Billerica, Massachusetts.
Aktiekurs
$56.53
Marknadsvärde
$8.61B
Förändring (1 dag)
2.09%
Förändring (1 år)
48.33%
Land
US
Handel Bruker Corporation (BRKR)
Kategori
Healthcare
P/E-tal för Bruker Corporation (BRKR)
P/E-tal per October 2026 TTM: -79.54
Enligt Bruker Corporation senaste finansiella rapporter och aktiekurs är det aktuella P/E-talet (TTM) -79.54. I slutet av 2023 hade företaget ett P/E-tal på 25.18.
Historik för P/E-tal för Bruker Corporation från 2000 till 2026
P/E-tal vid slutet av varje år
| År | P/E-tal | Ändra |
|---|---|---|
| 2026 (TTM) | -79.54 | -202.99% |
| 2024 | 77.23 | 206.68% |
| 2023 | 25.18 | -26.47% |
| 2022 | 34.24 | -25.31% |
| 2021 | 45.85 | -12.87% |
| 2020 | 52.62 | 31.18% |
| 2019 | 40.11 | 55.02% |
| 2018 | 25.88 | -62.52% |
| 2017 | 69.03 | 210.18% |
| 2016 | 22.26 | -44.61% |
| 2015 | 40.18 | -30.80% |
| 2014 | 58.06 | 41.29% |
| 2013 | 41.09 | 25.89% |
| 2012 | 32.64 | 46.67% |
| 2011 | 22.26 | -22.20% |
| 2010 | 28.61 | 17.80% |
| 2009 | 24.28 | 139.77% |
| 2008 | 10.13 | -85.11% |
| 2007 | 68.00 | 64.84% |
| 2006 | 41.25 | -69.31% |
| 2005 | 134.39 | -370.97% |
| 2004 | -49.60 | 85.31% |
| 2003 | -26.76 | -35.09% |
| 2002 | -41.23 | -116.97% |
| 2001 | 243.02 | -58.74% |
| 2000 | 589.00 | 0.00% |
P/E-tal för liknande företag eller konkurrenter
| Företag | P/E-tal | Skillnad i P/E-tal | Land |
|---|---|---|---|
| 33.11 | -141.62% |
US
|
|
| 21.39 | -126.89% |
IE
|
|
| 28.94 | -136.39% |
US
|
|
| 17.34 | -121.80% |
US
|
|
| - | - |
DE
|
Hur man läser ett P/E-tal
P/E-talet (Price/Earnings) mäter förhållandet mellan ett företags aktiekurs och dess vinst per aktie.
Ett lågt men positivt P/E visar ett företag med hög vinst i förhållande till värderingen och kan vara undervärderat. Ett högt negativt (nära 0) P/E indikerar stora förluster.
Företag med P/E över 30 eller negativt ses ofta som "tillväxtaktier", vilket innebär att investerare förväntar sig tillväxt eller framtida lönsamhet.
Företag med positivt P/E under 10 ses som "värdeaktier" och är redan lönsamma men med begränsad tillväxtpotential.